Loading organizations...
Attune Pharmaceuticals is a New York, New York-based biotechnology company that discovers and develops novel oral small-molecule therapeutics for the treatment of rare diseases. The organization primarily focuses on creating oral plasma kallikrein inhibitors, such as its lead drug candidate ATN-249, to treat patients suffering from Hereditary Angioedema. To support its pre-clinical and clinical research and development pipeline, the enterprise secured $23 million in a Series B financing round in November 2017. This capital injection was backed by notable institutional investors in the life sciences sector, including LifeSci Venture Partners and RTW Investments. Following this investment, the firm presented positive Phase 1 clinical trial data for its primary therapeutic candidate at the European Academy of Allergy and Clinical Immunology Congress. Attune Pharmaceuticals was established in 2015 by Andrew McDonald, who serves as chief executive officer.
Attune Pharmaceuticals has raised $23.0M across 1 funding round.
Attune Pharmaceuticals has raised $23.0M in total across 1 funding round.
Attune Pharmaceuticals has raised $23.0M in total across 1 funding round.
Attune Pharmaceuticals's investors include Venrock, ARCH Venture Partners, Boxer Capital, LifeSci Venture Partners, RA Capital Management, Roderick Wong, Tang Capital.
# Attune Pharmaceuticals: Biotechnology Company Overview
Attune Pharmaceuticals is a biotechnology company, not a technology company. The distinction is important: while biotech operates within the broader technology sector, it is specifically focused on drug development rather than software, hardware, or digital platforms.
Attune Pharmaceuticals is a private biotechnology company founded in 2018 and headquartered in New York that specializes in discovering and developing novel, orally-administered small-molecule therapeutics for rare diseases.[1] The company has raised $23 million in total funding and is advancing two primary programs: one targeting Hereditary Angioedema (HAE) and another addressing complement-mediated diseases.[1] Attune's mission centers on creating innovative treatments that empower clinicians to address unmet medical needs in rare disease populations where treatment options are limited.
The company serves patients and healthcare providers dealing with rare genetic and immunological disorders. By focusing on oral small-molecule drugs—which offer advantages in patient compliance and accessibility compared to injectable or infused therapies—Attune addresses a critical gap in the rare disease treatment landscape.
Attune operates within the growing rare disease therapeutics sector, where regulatory incentives (such as orphan drug designations) and unmet patient needs create compelling opportunities. The company's focus on small-molecule oral therapeutics aligns with industry trends favoring patient-friendly drug delivery mechanisms. As a private biotech firm with modest funding relative to larger pharmaceutical companies, Attune represents the type of specialized, disease-focused biotech that increasingly characterizes modern drug development—moving away from blockbuster approaches toward precision treatments for defined patient populations.
Attune's success will depend on advancing its HAE and complement-mediated disease programs through clinical development while maintaining adequate funding in a competitive biotech landscape. The company's emphasis on oral formulations and rare diseases positions it well for potential partnerships with larger pharmaceutical firms seeking to expand rare disease portfolios. As the rare disease market continues to attract investment and regulatory support, Attune's focused pipeline and experienced team suggest potential for meaningful clinical impact, though the typical biotech risks—clinical trial outcomes, regulatory approval timelines, and funding availability—remain significant factors in its trajectory.
Attune Pharmaceuticals has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series B in January 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2019 | $23M Series B | Venrock | ARCH Venture Partners, Boxer Capital, Lifesci Venture Partners, RA Capital Management, Roderick Wong, Tang Capital | Announced |
